Prinoxodan is primarily used in research settings as a selective phosphodiesterase III (PDE III) inhibitor. Its application is focused on studying cardiovascular functions, particularly in understanding the mechanisms of heart muscle contraction and relaxation. By inhibiting PDE III, it increases cyclic AMP levels, which enhances cardiac contractility and vasodilation. This makes it a valuable tool in exploring potential treatments for heart failure and other cardiovascular conditions. Additionally, it aids in investigating the role of PDE III in various physiological and pathological processes, contributing to the development of novel therapeutic strategies.